@article {44430,
	title = {Chemo-biological evaluation of antidiabetic activity of M entha arvensis L. and it{\textquoteright}s role in inhibition of advanced glycation end products},
	journal = {Journal of Ayurveda and integrative medicine},
	year = {2018},
	month = {FEB},
	abstract = {<p>Background: There has been enormous curiosity in the development of alternative plant based medicines to control diabetes, oxidative stress and related disorders. One of the therapeutic approaches is to reduce postprandial release of glucose in the blood. Two key enzymes that are involved in reducing postprandial glucose are α-amylase and α-glucosidase. Mentha arvensis L. has been traditionally used by several tribes as a medicinal plant to treat various disorders. Objective: The present study was undertaken to test M. arvenisis L. for inhibition of postprandial hyperglycemia. Material and method: We performed various in vitro and in vivo tests to evaluate efficacy of M. arvenisis L. for antidiabetic activity (postprandial hyperglycemia). Results: Methanolic extract of M. arvensis L. leaves showed DPPH free radical scavenging activity (more than 78\% μg/μl) and high antiglycation potential (more than 90\% inhibition of AGE formation). Methanolic extract also showed remarkable inhibitory effects on α-amylase (more than 50\% μg/μl) and α-glucosidase (68\% μg/μl) and significant inhibition of postprandial hyperglycemia in starch induced diabetic Wistar rats. Conclusion: The non-insulin dependent antidiabetic or inhibition of postprandial hyperglycemic activity of methanolic extract of M. arvensis L. leaves was shown by using in vitro and in vivo approaches in the present study.</p>},
	doi = {10.1016/j.jaim.2017.07.003},
	author = {Agawane, Sachin B. and Gupta, Vidya S. and Kulkarni, Mahesh J. and Bhattacharya, Asish K. and Koratkar, Santosh}
}
@article {49548,
	title = {Characterization of novel phages KPAФ1, KP149Ф1, and KP149Ф2 for lytic efficiency against clinical MDR Klebsiella pneumoniae infections},
	journal = {Microbial Pathogenesis},
	volume = {202},
	year = {2025},
	month = {MAY},
	pages = {107440},
	type = {Article},
	abstract = {<p>
	Phage therapy offers a promising approach to the increasing antimicrobial resistance of Klebsiella pneumoniae. This study highlights three novel lytic bacteriophages-KPAc1, KP149c1, and KP149c2-targeting multidrugresistant (MDR) K. pneumoniae. These phages belong to the Myoviridae and Podoviridae family and demonstrate their efficacy and stability across a wide range of temperatures (up to 60 degrees C) and pH levels (pH 4 to 11). Genomic analysis reveals that they are free from virulence, toxicity, and antimicrobial resistance genes, making them promising candidates for therapeutic use. Among these phages, KPAc1 showed the highest lytic activity with a 26.15\% lysis against MDR K. pneumoniae isolates. Additionally, a phage cocktail comprising all three phages improved lytic efficacy to 32.30\%. This study also examined the antimicrobial resistance profiles of K. pneumoniae isolates, emphasizing the critical need for alternative treatments. By effectively targeting resistant strains, these phages offer a potential candidacy to be used as a viable alternative or a complementary antimicrobial agent to traditional antibiotics, opening up the possibility for advanced phage-based therapies. The promising results from this study pave the way for developing new treatments that could significantly improve patient care and outcomes from the growing issue of resistant bacterial infections.</p>
},
	keywords = {Antimicrobial resistance, Bacteriophage, MDR-Klebsiella pneumoniae, Phage cocktail, Phage therapy},
	issn = {0882-4010},
	doi = {10.1016/j.micpath.2025.107440},
	author = {Dandekar, Shraddha S. and Thanikkal, Sinta and Londhe, Arti and Bhutada, Pankhudi and Saha, Ujjayni and Pawar, Shubhankar and Samson, Rachel and Dharne, Mahesh and Saroj, Sunil D. and Koratkar, Santosh}
}
